Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

LK, Mell; PA, Torres-Saavedra; SJ, Wong; JA, Kish; SS, Chang; RC, Jordan; T, Liu; MT, Truong; EW, Winquist; V, Takiar; T, Wise-Draper; JR, Robbins; CP, Rodriguez; MJ, Awan; BM, Beadle; C, Henson; S, Narayan; SA, Spencer; S, Powell; N, Dunlap; AG, Sacco; KS, Hu; HS, Park; JE, Bauman; J, Harris; SS, Yom; QT, Le

doi:10.1016/s1470-2045(24)00507-2

Public

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

Shared by NobleBlocks on Nov 14, 2024 • 12:00 AM UTC

Authors:

Mell LK

Torres-Saavedra PA

Wong SJ

Abstract

<h4>Background</h4>Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy w...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!